Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ji-Yang Shen"'
Autor:
Fang‐fang Li, Wei‐jun Chen, Dan Yao, Lin Xu, Ji‐yang Shen, Yan Zeng, Zhuo Shi, Xiao‐wei Ye, Dao‐huan Kang, Bin Xu, Jie Shao, Chai Ji
Publikováno v:
Molecular Genetics & Genomic Medicine, Vol 10, Iss 12, Pp n/a-n/a (2022)
Abstract Background Williams syndrome (WS) is a multisystem neurodevelopmental disorder caused by microdeletions in 7q11.23. This study aims to characterize the clinical phenotypes of Chinese children with WS to help for the early diagnosis and inter
Externí odkaz:
https://doaj.org/article/874a37b2669c443ab05240cd10b9ff8c
Publikováno v:
Brazilian Journal of Pharmaceutical Sciences, Vol 54, Iss 4 (2019)
Psoriasis is a T-cell mediated disease that involves IL-23/Th17 and IL-12/Th1 axes. Ustekinumab, a fully human monoclonal antibody targeting the p40 subunit of both IL-12 and IL-23, has proven to be efficient and safe for treating patients with psori
Externí odkaz:
https://doaj.org/article/3a6b7607429d482b8a41bc260a333657
Publikováno v:
International Journal of Medical Sciences. 19:1796-1805
Publikováno v:
Brazilian Journal of Pharmaceutical Sciences, Volume: 58, Article number: e19685, Published: 13 JUL 2022
Psoriasis is a chronic skin inflammation, characterized by impaired differentiation, hyperproliferation of keratinocytes involving pro-inflammatory factors interleukin (IL)-13/17A, tumor necrosis factor (TNF)-α, interferon (IFN)-γ. Among the integr
Background: Keloids represent the dysregulation of cutaneous wound healing caused by aberrant fibroblast activities. Adipose-derived stem cells have been recognized as a promising treatment for keloids. However, their molecular mechanisms have not be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03c8f4dee58627172506733e6954745a
https://doi.org/10.21203/rs.3.rs-149077/v1
https://doi.org/10.21203/rs.3.rs-149077/v1
Publikováno v:
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
BACKGROUND Ustekinumab, a human-derived monoclonal antibody that targets the p40 subunit of interleukin (IL)-12 and IL-23, has excellent clinical efficacy and safety in treating psoriasis, with a long half-life. However, no reports have described the
Publikováno v:
Brazilian Journal of Pharmaceutical Sciences, Volume: 54, Issue: 4, Article number: e17349, Published: 08 APR 2019
Brazilian Journal of Pharmaceutical Sciences, Vol 54, Iss 4 (2019)
Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 4 (2018); e17349
Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 4 (2018); e17349
Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 4 (2018); e17349
Brazilian Journal of Pharmaceutical Sciences
Universidade de São Paulo (USP)
instacron:USP
Brazilian Journal of Pharmaceutical Sciences, Vol 54, Iss 4 (2019)
Brazilian Journal of Pharmaceutical Sciences; Vol. 54 No. 4 (2018); e17349
Brazilian Journal of Pharmaceutical Sciences; Vol. 54 Núm. 4 (2018); e17349
Brazilian Journal of Pharmaceutical Sciences; v. 54 n. 4 (2018); e17349
Brazilian Journal of Pharmaceutical Sciences
Universidade de São Paulo (USP)
instacron:USP
Psoriasis is a T-cell mediated disease that involves IL-23/Th17 and IL-12/Th1 axes. Ustekinumab, a fully human monoclonal antibody targeting the p40 subunit of both IL-12 and IL-23, has proven to be efficient and safe for treating patients with psori
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ab83c55d1c6f7ff4684d0fc7393b6cd
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502018000400615&lng=en&tlng=en
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502018000400615&lng=en&tlng=en
Publikováno v:
Medical Science Monitor; 1/7/2020, Vol. 26, p1-8, 8p